us en false false
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF Please read important disclosure Close important disclosure false

PPH
VanEck Pharmaceutical ETF

PPH
VanEck Pharmaceutical ETF

  • NAV
    $88.63

    as of November 22, 2024
  • YTD RETURNS
    10.50%

    as of November 22, 2024
  • Total Net Assets
    $606.06M

    as of November 22, 2024
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011

Fund Description

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Buy Now
Schedule a Call
Sign Me Up

Overview

Fund Highlights

  • Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume

  • Industry Leaders
    Index methodology favors the largest companies in the industry

  • Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Performance

Fees

Holdings

Portfolio

Distributions

Team

Literature

PPH